Shilajit for women, and what the evidence in women actually consists of

Only two published trials have enrolled women and measured anything. One took skin biopsies from 45 women over 14 weeks and read gene expression. The other measured bone mineral density in 60 postmenopausal women with osteopenia over 48 weeks. Both are small, both tested a standardised extract rather than a jar of resin, and neither measured oestrogen. That is the entire evidence base behind the phrase “shilajit benefits for women”, and almost every page ranking for it is extrapolating from trials run in men.

That is not a reason to dismiss the substance. It is a reason to know exactly what you are buying into. Below: what each of those two trials actually did, why iron is the one compositional question that changes the answer depending on who you are, what the menopause searches are really asking, and the one situation where the answer is short and absolute.

How we read a claim about shilajit in women

Most articles on this subject fail at the same point. They quote a study, do not say who was in it, and let you assume the population was you. These are the seven checks we run before a sentence about women goes on this page.

Population. Were women in the trial at all, and how many? A 2026 open-label resin pilot published in Cureus enrolled 25 participants, every one of them male. It is still cited on pages titled “shilajit benefits for females”. The sex of the cohort is the first thing we look for and the thing most commonly left out.

Endpoint class. A trial either measures a clinical outcome you would notice, such as bone mineral density on a scan, or it measures a surrogate: gene transcripts, blood markers, imaging-derived redness. Both are legitimate science. Only one of them tells you something changed in a way a person would recognise.

Preparation identity. Resin, liquid, powder and standardised extract are not interchangeable. Both trials in women used a standardised aqueous extract at a defined milligram dose. A spoon of resin is a different material with a different composition, and no trial in women has tested one.

Duration against the biology. Bone remodelling is slow, so a bone trial needs a year, and the one that exists ran 48 weeks. Skin gene expression can shift in weeks. Judging a 14-week skin study by the standards of a bone study, or the reverse, produces nonsense in both directions.

Who paid. The skin study states it was supported in part by a research grant from the company that manufactures the shilajit extract it tested. That does not make the data wrong. It does mean an independent replication would carry more weight, and there is not one.

What was not measured. Every trial has a list of things it did not look at, and that list is usually longer than the results. We state it in every section below, because it is the part that decides whether a claim is honest.

Replication. One trial is a finding. Two independent trials pointing the same way are evidence. On this subject, in women, nothing has been repeated by a second group.

The skin study: 45 women, 14 weeks, and what it read

This is the paper sitting at position two on the English search results, and almost nobody quoting it has opened it. Das and colleagues published it in the Journal of the American College of Nutrition in 2019, titled “Skin Transcriptome of Middle-Aged Women Supplemented With Natural Herbo-mineral Shilajit Shows Induction of Microvascular and Extracellular Matrix Mechanisms”.

Forty-five healthy women aged 30 to 65, mean age 42, mean body mass index 29.5, were randomised into three groups of fifteen: placebo, 125 mg of shilajit twice daily, or 250 mg twice daily. The study ran 14 weeks across six visits. Skin biopsies were taken from the left inner upper arm at week 2 and week 14 and profiled on an Affymetrix Clariom D array, with RT-PCR validation. Skin perfusion was estimated from dermascopic images processed in MATLAB.

At the 250 mg dose, roughly 5,000 probe sets were differentially regulated. Genes coding collagens, including COL1A1, COL5A2 and COL14A1, were upregulated, alongside a set associated with blood vessel formation and extracellular matrix turnover. The imaging measure of skin redness changed at 250 mg twice daily and did not change at 125 mg.

Now the part that is missing everywhere else. Analyses were reported on roughly 10 to 14 women per group, not 15. The study measured transcripts and an imaging proxy. It did not measure wrinkles, elasticity, hydration or pigmentation, it did not assess anything a participant could see in a mirror, and it did not ask participants what they thought had changed. It was supported in part by the manufacturer of the extract it tested. No independent group has repeated it.

So the accurate sentence is narrow: in 45 middle-aged women taking 250 mg twice daily for 14 weeks, skin biopsies showed changes in gene expression, and no clinical skin outcome was assessed. Anything beyond that sentence is somebody’s inference, not the study’s result.

The bone trial: 60 postmenopausal women, 48 weeks

The second trial is the one that deserves the attention the skin study gets. Pingali and Nutalapati published it in Phytomedicine in 2022, run at Nizam’s Institute of Medical Sciences in Hyderabad.

Sixty postmenopausal women aged 45 to 65 with osteopenia were randomised double-blind to placebo, 250 mg of shilajit extract daily, or 500 mg daily, for 48 weeks. Bone mineral density of the lumbar spine and femoral neck was scanned at weeks 0, 24 and 48. Blood markers of bone turnover (CTX-1, BALP, RANKL, OPG), oxidative stress (MDA, GSH) and inflammation (hsCRP) were taken at weeks 0, 12, 24 and 48.

Bone mineral density at both sites fell over the year in the placebo group. In both supplemented groups it fell less, and the percentage change from baseline differed significantly from placebo at 24 and 48 weeks in a dose-dependent pattern. The turnover, oxidative stress and inflammation markers moved in the corresponding direction from week 12 onward.

What it does not establish: it was a single centre, in one country, in one narrowly defined population, women who already had osteopenia. It has not been replicated. It tested a specific standardised aqueous extract at a measured dose, not resin from a jar. And it says nothing about women who do not have osteopenia, which is most readers of this page.

	Skin trial (Das, 2019)	Bone trial (Pingali, 2022)
Participants	45 women, aged 30 to 65	60 postmenopausal women, aged 45 to 65
Design	Randomised, placebo-controlled	Randomised, double-blind, placebo-controlled
Dose	125 mg or 250 mg twice daily	250 mg or 500 mg daily
Duration	14 weeks	48 weeks
Endpoint class	Surrogate: gene expression	Clinical: bone mineral density scan
Replicated	No	No

If you read one thing on this page and stop, read that table. Two trials, both small, one surrogate endpoint and one clinical endpoint, neither repeated.

Is shilajit good for women, and what effect does it have?

The German search is blunter than the English one: what effect does shilajit have on women. The answer that survives scrutiny is that outside skin gene expression over 14 weeks and bone density over 48 weeks, nothing has been measured in women, so nothing can be stated. Spanish searchers ask what shilajit is used for in women, and the honest answer is that people use it as a daily mineral-rich food supplement for the same unremarkable reasons men do.

That is an unsatisfying answer, and it is the correct one. The alternative is what the current top result does: assert an effect on hormones, on periods, on skin and on energy in a single paragraph, with no trial, no dose and no population attached to any of it. We are not going to write that, partly because it is not established and partly because it is not permitted. Shilajit is sold in the EU, the UK and Switzerland as a food supplement, and no health claim for it has been authorised under Regulation (EC) 1924/2006.

The rest of the evidence base, which is genuinely interesting, was run in men: a testosterone trial in men aged 45 to 55, a strength trial, a fatigue trial. We keep that ground on its own page, the men-specific evidence, and the trial-by-trial summary on shilajit benefits. Reading a men’s trial as though it applied to you is the most common error in this category, and searches phrased as benefits of shilajit for women, shilajit benefits for ladies or shilajit uses for women almost all land on pages that make it.

Does shilajit increase oestrogen?

No randomised, placebo-controlled trial in women has reported oestrogen, spelled estrogen in most of the sources, as an outcome. There is no number to quote, in either direction.

This matters more than it sounds, because the claim is everywhere. It is built by taking the 2016 Andrologia trial, which reported higher testosterone in men aged 45 to 55 after 90 days at 250 mg twice daily, and reasoning by analogy to a different hormone in a different sex. That is not how endocrinology works and it is not how evidence works.

The bone trial is the closest anything comes, and it is not close. It enrolled postmenopausal women precisely because oestrogen is already low in that group, and it measured bone markers, not hormones. If someone tells you a supplement raises or lowers your oestrogen, ask for the trial, the dose, the duration and the assay. On this substance, in women, there is no such trial.

Shilajit and menopause: what those searches are really asking

Menopause is where this keyword cluster concentrates outside English. German searchers ask whether shilajit is good against menopause complaints. Italian, French and Polish searchers ask the same thing in fewer words.

Nothing has measured that. Not hot flushes, not night sweats, not sleep, not mood, not joint pain, not concentration. The single trial in postmenopausal women scanned bones and drew blood in women who already had osteopenia. Bone density is a real menopause-related concern, and it is not what most people mean when they type the question.

If bone density is your actual concern, the conversation to have is with a doctor about a DEXA scan, calcium and vitamin D intake, resistance training and, where indicated, prescribed treatment. A food supplement is not a substitute for any of that, and one 48-week trial in 60 women at a single Indian hospital does not change the order of those priorities.

Iron, and why it cuts both ways

Shilajit is routinely described as iron-rich, and this is the one compositional fact that changes the answer depending on who you are. It deserves more care than it usually gets.

Start with what is actually known. A 2025 chemical analysis in ACS Omega characterised a single native Himalayan specimen from Uttarkashi using microwave plasma atomic emission spectroscopy and X-ray fluorescence. Potassium, magnesium, calcium and sodium came out as the predominant elements. Iron was reported below the detection threshold of the method, as were lead, arsenic, chromium and cobalt. The authors are explicit that this is one specimen, offered as a compositional reference point rather than as a description of all shilajit.

So the position is this. Composition varies by site, altitude, season and purification, and the only way to know what is in a specific jar is a batch analysis of that jar. “Shilajit is iron-rich” is a generalisation about a category, not a measured fact about the product in front of you, and it can be wrong in either direction.

Two readers should care about this in opposite ways. If you have been told your iron is low, a food supplement of unquantified iron content is not the answer; a blood test and a clinician-directed iron supplement is. And if you have haemochromatosis, iron builds up in the body over years and, untreated, can damage the liver, joints, pancreas and heart. NHS advice for that condition includes avoiding iron supplements and iron-fortified foods. Shilajit belongs in that conversation with your doctor before it belongs in your cupboard, not after.

Whichever side you are on, that is a question about your blood results, not about a jar. The related chemistry sits on the fulvic acid page, and the contamination question, which is separate and more important, is covered under heavy metals and lab testing.

Pregnancy and breastfeeding: do not take it

Do not take shilajit if you are pregnant, breastfeeding, or trying to conceive. Speak to your midwife or your doctor.

That is the whole answer and it is not hedged. No trial has tested shilajit in pregnancy or during breastfeeding. There is no safety data, no established dose, and no way to characterise the risk. The material is a mineral-rich natural substance whose composition varies by source, which is precisely the profile that pregnancy guidance approaches with caution.

The NHS position on supplements in pregnancy is narrow and specific: folic acid, and vitamin D through the darker months, with an explicit instruction not to take supplements containing vitamin A. Iron is given when a blood test indicates it, prescribed by a GP or midwife, at a known dose. That is the standard shilajit does not meet. Nothing about it is measured for this population, and nothing about it is prescribed.

If you have already taken shilajit and then discovered you are pregnant, do not panic and do not guess. Stop, and tell your midwife or doctor what you took, how much and for how long. That is a conversation they have every week about all sorts of supplements.

Who should avoid taking shilajit

Beyond pregnancy and breastfeeding, the exclusion list is short and it is not negotiable. The full version, with the reasoning behind each entry, lives on shilajit side effects. The essentials:

• Anyone with haemochromatosis or another iron-overload condition, without their doctor’s explicit agreement.
• Children.
• Anyone taking prescribed medication. Speak to a pharmacist first, because they can check interactions in minutes and it costs nothing.
• Anyone with a diagnosed condition who has not raised it with their clinician.
• Anyone holding raw, unpurified material of unknown origin, whatever their health status.

On reported side effects, be precise about the limits. The 2026 Cureus resin pilot recorded mild, self-limiting events in 7 of 25 participants over 28 days, including acne, rash, itching, abdominal pain and dyspepsia, with no serious adverse events. Every participant was male, it was open-label with no placebo group, and 25 people over four weeks cannot characterise anything. No published trial has reported shilajit side effects for female participants separately.

What reviews and personal reports can and cannot tell you

A large share of the non-English search volume is people looking for other women’s experiences: reviews, forum threads, before-and-after accounts. That instinct is sound, because you want to know what happens to someone like you.

Here is the limit. Anecdote cannot separate an effect from an expectation, or from a seasonal change, or from the fact that people usually start a supplement in a week when they have also decided to sleep more and drink less. The skin trial had a placebo group for exactly this reason. Personal reports are useful for two things: taste and tolerability. They will tell you honestly that the resin is bitter and smoky, and that some people find it hard going on an empty stomach. They will not tell you whether it did anything.

Read reviews for logistics. Read trials for effects. Do not swap them.

What is still not known

Almost everything. No trial in women has measured energy, sleep, mood, cognition, menstrual cycles, menopause symptoms, hormones of any kind, iron status, or safety beyond 48 weeks. No trial in women has tested resin. No result in women has been independently replicated. Two studies, around 105 women in total, both with limitations a careful reader should weigh.

We sell this product and we are telling you that. It is a better basis for a decision than a page that fills the same gap with confident adjectives.

If you are deciding whether to try it

Three things decide this, and none of them is a benefit list. First, whether you are in an excluded group: pregnant, breastfeeding, trying to conceive, iron-overloaded, on prescribed medication. If you are, the decision is already made. Second, whether you can see a current batch analysis for the specific jar you are buying, because contamination is the real risk in this category and it is entirely avoidable. Third, whether you are comfortable spending money on a substance whose evidence in women amounts to two unreplicated trials, which is a legitimate thing to decline.

If you have read all of that and still want to try it, buy purified resin with published testing behind it, and give it a fair trial at a consistent daily amount rather than sampling it for a week. Our shilajit resin is sold with that expectation, and the practical side, how much, when, and how to dissolve it, is covered on how to take shilajit.